A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Angelman syndrome
- Focus Adverse reactions
- Acronyms STARS
- Sponsors Ovid Therapeutics
- 29 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 29 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 28 Nov 2017 According to an Ovid Therapeutics media release, the company expects data from the trial to be available in second half of 2018.